|drug1238||Exercise training group Wiki||1.00|
|D051436||Renal Insufficiency, Chronic NIH||0.58|
|D007154||Immune System Diseases NIH||0.45|
|D007674||Kidney Diseases NIH||0.45|
There is one clinical trial.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality.
Description: Number of participants who dieMeasure: All-cause mortality Time: During hospitalization or until death, whichever comes first, assessed up to 30 days
Description: Number of participants who require intubation for mechanical ventilation or dieMeasure: Composite outcome:composite of intubation for mechanical ventilation or death. Time: During hospitalization or until death, whichever comes first, assessed up to 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports